TSLP and chronic rhinosinusitis with nasal polyps: Several monoclonal antibodies (mAbs) targeting distinct type 2 inflammatory players (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab targeting IgE, IL-5, IL-5 receptor, IL-4 receptor, and TSLP, respectively), initially available for the treatment of severe asthma only, were found to significantly reduce CRSwNP inflammation and symptoms when used to treat comorbid patients.